![]() |
Name |
penicophenone B
|
Molecular Formula | C18H20O6 | |
IUPAC Name* |
1-[2,4-dihydroxy-3-[(4-hydroxy-2,5-dimethoxyphenyl)methyl]-5-methylphenyl]ethanone
|
|
SMILES |
COc1cc(Cc2c(O)c(C)cc(C(C)=O)c2O)c(OC)cc1O
|
|
InChI |
InChI=1S/C18H20O6/c1-9-5-12(10(2)19)18(22)13(17(9)21)6-11-7-16(24-4)14(20)8-15(11)23-3/h5,7-8,20-22H,6H2,1-4H3
|
|
InChIKey |
MPKMTYGPQBPDNO-UHFFFAOYSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 332.35 | ALogp: | 2.9 |
HBD: | 3 | HBA: | 6 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 96.2 | Aromatic Rings: | 2 |
Heavy Atoms: | 24 | QED Weighted: | 0.722 |
Caco-2 Permeability: | -4.966 | MDCK Permeability: | 0.00000989 |
Pgp-inhibitor: | 0.048 | Pgp-substrate: | 0.623 |
Human Intestinal Absorption (HIA): | 0.022 | 20% Bioavailability (F20%): | 0.105 |
30% Bioavailability (F30%): | 0.012 |
Blood-Brain-Barrier Penetration (BBB): | 0.009 | Plasma Protein Binding (PPB): | 97.63% |
Volume Distribution (VD): | 0.358 | Fu: | 3.96% |
CYP1A2-inhibitor: | 0.351 | CYP1A2-substrate: | 0.953 |
CYP2C19-inhibitor: | 0.217 | CYP2C19-substrate: | 0.318 |
CYP2C9-inhibitor: | 0.521 | CYP2C9-substrate: | 0.71 |
CYP2D6-inhibitor: | 0.232 | CYP2D6-substrate: | 0.712 |
CYP3A4-inhibitor: | 0.161 | CYP3A4-substrate: | 0.448 |
Clearance (CL): | 13.222 | Half-life (T1/2): | 0.871 |
hERG Blockers: | 0.063 | Human Hepatotoxicity (H-HT): | 0.172 |
Drug-inuced Liver Injury (DILI): | 0.517 | AMES Toxicity: | 0.043 |
Rat Oral Acute Toxicity: | 0.172 | Maximum Recommended Daily Dose: | 0.356 |
Skin Sensitization: | 0.921 | Carcinogencity: | 0.055 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.884 |
Respiratory Toxicity: | 0.2 |